Cerity Partners
MRSN

Cerity Partners’s Mersana Therapeutics MRSN Stock Holding History

Cerity Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,832
Closed -$95K – 2823
2025
Q2 		$95K Buy
12,832
+3,063
+31% +$26.9K ﹤0.01% 2487
2025
Q1 		$84.1K Buy
+9,769
New +$151K ﹤0.01% 2342

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cerity Partners's MRSN Position: Q3 2025 in Review

Cerity Partners sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 12,832 shares — an estimated $95K sold.

Cerity Partners first reported a position in MRSN in Q1 2025 and held it in 2 quarters. The position peaked at $95K in Q2 2025. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Cerity Partners reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cerity Partners sold 12,832 Mersana Therapeutics shares in Q3 2025, an estimated $95K.
  • Cerity Partners first reported a position in Mersana Therapeutics in Q1 2025 and held it in 2 quarters.
  • Cerity Partners's Mersana Therapeutics position peaked at $95K in Q2 2025.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Cerity Partners's 13F filing for Q3 2025, filed 22 Oct 2025.